NHS Choices, the online 'front door' for the NHS, has released an updated online information resource aimed at helping the …
Government and BMA relations have hit an all time low, with the doctor's association accusing ministers of undermining its position …
Research charity the Wellcome Trust will increase its funding for medical research by more than £1 billion over the next …
Swedish biopharmaceutical company Biovitrum is to turn its back on mass market disease areas and re-focus around specialist care projects. …
Coronado Biosciences’ cancer treatment effective in animal modelsCoronado Biosciences has reported that the Bcl-2 inhibitor, apogossypol, effectively killed a variety …
Pharma companies should engage diagnostics companies in early phase talks if they want to fast-track innovative new cancer treatments to …
Takeda has bought marketing rights to 13 of Amgen's early stage products, boosting its flagging pipeline and letting Amgen recoup …
New guidelines to help NHS bodies work with the pharmaceutical industry have been agreed after months of negotiation, and could …
The Department of Health has reorganised the way audits of patient care are carried out, handing the running of its …
Wyeth's new cancer drug Torisel is set to gain approval for use in patients with a rare and difficult to …
Sales of the blockbuster flu treatment Tamiflu could receive a setback from new data showing significant resistance to the drug. …
AstraZeneca achieved sales growth of 12% in 2007, despite a worrying decline in sales from its biggest seller, anti-ulcer drug …
Avastin has won a broader European licence for metastatic colorectal cancer, a move manufacturer Roche believes will make it more …
The Pharmaceutical Marketing Society’s Advertising Awards added their customary sparkle to the grey month of January, and celebrated the best …
France has re-branded its leading biotech cluster the ‘Alsace Biovalley’ to help the region compete for investment in Europe and …
Q: Europe’s biggest market Germany is preparing for some major reforms at the moment. How is Novartis responding to that …